BNP Paribas Financial Markets Has $2.83 Million Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

BNP Paribas Financial Markets cut its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 58.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,444 shares of the medical research company's stock after selling 11,995 shares during the quarter. BNP Paribas Financial Markets' holdings in Bio-Rad Laboratories were worth $2,825,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Capital Advisors Ltd. LLC boosted its stake in Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after purchasing an additional 62 shares during the period. UMB Bank n.a. boosted its position in shares of Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock valued at $26,000 after acquiring an additional 45 shares during the period. Gladius Capital Management LP acquired a new position in shares of Bio-Rad Laboratories in the third quarter valued at about $32,000. Headlands Technologies LLC acquired a new position in shares of Bio-Rad Laboratories in the second quarter valued at about $51,000. Finally, Quarry LP bought a new position in Bio-Rad Laboratories during the second quarter worth about $59,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Analyst Ratings Changes

BIO has been the subject of a number of recent research reports. StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Citigroup increased their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 price objective on the stock. Finally, Royal Bank of Canada upped their target price on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a research report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Bio-Rad Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Price Performance

BIO traded up $3.14 during trading on Friday, hitting $325.50. 151,133 shares of the stock traded hands, compared to its average volume of 243,193. The business has a 50 day moving average price of $341.34 and a 200 day moving average price of $318.77. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99. The company has a market cap of $9.11 billion, a price-to-earnings ratio of -12.00 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.16 by $0.85. The company had revenue of $649.70 million during the quarter, compared to analysts' expectations of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. Bio-Rad Laboratories's revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.33 EPS. Equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.